A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age (NCT07406360)
A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age
🩺 Plain-English Summary (8th-Grade Level)
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Birmingham, Alabama
Age range: 15 Months to 6 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- GSK Investigational Site — Birmingham, Alabama
- GSK Investigational Site — Walnut Creek, California
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Farmington Hills, Michigan
- GSK Investigational Site — Dayton, Ohio
- GSK Investigational Site — Simpsonville, South Carolina
- GSK Investigational Site — Spartanburg, South Carolina
- GSK Investigational Site — Frisco, Texas
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Port Lavaca, Texas
- GSK Investigational Site — Richmond, Texas
- GSK Investigational Site — Provo, Utah
- GSK Investigational Site — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Measles
Explore by condition: All Measles clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.